^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Excerpt:
...- EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fusions (Cohort C)...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

NSCLC Exon 20 or HER2-activating Mutations

Excerpt:
...- EGFR exon 20 insertion mutation (Cohort A) or HER2-activating mutation (Cohort B)...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: D – Preclinical
Title:

Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

Published date:
12/22/2020
Excerpt:
Novel and existing patient-derived cell lines and xenografts harboring EGFR exon 20 insertion mutations, ERBB2 (HER2) mutations and amplification, and NRG1 fusions were tested in vitro and in vivo with tarloxotinib...Tarloxotinib-E inhibited cell signaling and proliferation in patient-derived cancer models in vitro...In vivo, tarloxotinib induced tumor regression or growth inhibition in multiple murine xenograft models.
DOI:
10.1158/1078-0432.CCR-20-3555